

drug products covered by this notice that are marketed under an NDC number listed with the Agency in full compliance with section 510 of the FD&C Act before March 2, 2011. As previously stated, drug products covered by this notice that are currently marketed but not listed with the Agency on the date of this notice must, as of the effective date of this notice, have approved applications prior to their shipment in interstate commerce. Moreover, any person or firm that has submitted or submits an application but has yet to receive approval for such products is still responsible for full compliance with this notice.

#### V. Discontinued Products

Some firms may have previously discontinued the manufacturing or distribution of products covered by this notice without removing them from the listing of their products under section 510(j) of the FD&C Act. Other firms may discontinue manufacturing or marketing listed products in response to this notice. Firms that wish to notify the Agency of product discontinuation should send a letter, signed by the firm's chief executive officer, fully identifying the discontinued product(s), including NDC number(s), and stating that the product(s) has (have) been discontinued. The letter should be sent to Sakineh Walther (*see ADDRESSES*). Firms should also update the listing of their products under section 510(j) of the FD&C Act to reflect discontinuation of products covered by this notice. FDA plans to rely on its existing records, including its drug listing records, or other available information when it targets violations for enforcement action.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sections 502 and 505 (21 U.S.C. 352 and 355)) and under authority delegated to the Assistant Commissioner for Policy under section 1410.21 of the FDA Staff Manual Guide.

Dated: February 22, 2011.

**Leslie Kux,**

*Acting Assistant Commissioner for Policy.*

[FR Doc. 2011-4703 Filed 3-2-11; 8:45 am]

**BILLING CODE 4160-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Advisory Committee on Organ Transplantation; Notice of Meeting

**AGENCY:** Health Resources and Services Administration, HHS.

**ACTION:** Notice; correction.

**SUMMARY:** The Health Resources and Services Administration published a notice in the **Federal Register** of February 9, 2011 (76 FR 7223-7224) announcing an Advisory Committee on Organ Transplantation meeting on March 8, 2011. The type of meeting, time and place have been changed.

#### Correction

In the **Federal Register** of February 9, 2011, in FR Doc. 2011-2839, on page 7223, 2nd column, under the heading Department of Health and Human Services, Health Resources and Services Administration, Advisory Committee on Organ Transplantation; Notice of Meeting, change the Times and Place to read:

The meeting will be an Audio Conference Call on March 8, 2011, from 12 noon to 4 p.m. EST. To access the conference call, call the USA Toll Free Number 888-469-1090 and enter the Passcode 2741198. The conference call leader is Patricia A. Stroup. Participants should call no later than 11:45 a.m. EST in order for logistics to be set up. Participants are asked to register for the conference call by contacting Brittany Carey, HRM/Professional and Scientific Associates (PSA), the logistical support contractor for the meeting, at (703) 889-9033 or *b\_carey@team-psa.com*. The registration deadline is March 7, 2011. The Department will try to accommodate those wishing to participate in the call.

The next face-to-face ACOT meeting is planned for August 2011. Details regarding an August meeting will be published in a subsequent **Federal Register** notice.

**Reva Harris,**

*Acting Director, Division of Policy and Information Coordination.*

[FR Doc. 2011-4755 Filed 3-2-11; 8:45 am]

**BILLING CODE 4165-15-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Aging; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Aging Special Emphasis Panel; Member Conflict.

*Date:* March 15, 2011.

*Time:* 9 a.m. to 10 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Ramesh Vemuri, PhD, Chief, Scientific Review Branch, National Institute on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Suite 2C-212, Bethesda, MD 20892, 301-402-7700, *rv23r@nih.gov*.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: February 25, 2011.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2011-4826 Filed 3-2-11; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Research Resources; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections